Rapid Communication
Copyright ©2006 Baishideng Publishing Group Co.
World J Gastroenterol. Nov 7, 2006; 12(41): 6715-6721
Published online Nov 7, 2006. doi: 10.3748/wjg.v12.i41.6715
Table 1 Characteristics of the patients at entry to the study1
CharacteristicsHBeAg-positive CHB
T-α1 groupIFN-α groupHC group
Number293330
Male: Female26:327:621:9
Age (yr)245 ± 842 ± 1144 ± 10
Duration of infection (yr)210.8 ± 5.69.3 ± 4.79.6 ± 5.5
Cirrhosis at entry232
Previous 1FN therapy200
Serum ALT (U/L)2177.79 ± 58.82189.94 ± 63.08183.5 ± 68.32
Serum AST (U/L)167.72 ± 34.19154.27 ± 73.34141.8 ± 49.85
Albumin (g/L)244 ± 947 ± 845 ± 8
Total bilirubin (μmol/L)18.57 ± 9.6517.92 ± 9.2216.68 ± 8.72
Serum HBV DNA (copies/mL)3
< 5.0 × 105 copies/mL10 (34%)15 (45%)13 (43%)
≥ 5.0 × 105 copies/mL19 (66%)18 (55%)17 (57%)
Table 2 Response to treatment at the end of therapy n (%)
T-α1 (n = 29)IFN-α (n = 33)HC (after 6 mo of follow-up) (n = 30)
ALT normalization11 (37.9)16 (48.5)b5 (16.7)
Negative HBV DNA16 (55.2)c22 (66.7)c2 (6.7)
ALT normal/nagative HBeAg & HBVDNA9 (31.0)b15 (45.5)c1 (3.3)
Table 3 Response to treatment at the end of follow-up n (%)
T-α1 (n = 29)IFN-α (n = 33)HC (after 12 mo of follow-up) (n = 30)
ALT normalization17 (58.6)cf10 (30.3)3 (10)
Negative HBV DNA21 (72.4)df13 (39.4)b2 (6.7)
ALT normal/nagative HBeAg & HBVDNA14 (48.3)f9 (27.3)a1 (3.3)
HBeAg & HBV DNA
Table 4 Response to treatment between thymosin-a1 & IFN-a groups
At the end of therapy OR (95% CI)At the end of follow-up OR (95% CI)
ALT normalization0.65 (0.21, 2.01)3.19 (1.02, 10.61)a
HBVDNA-negation0.62 (0.19, 1.94)3.94 (1.23, 13.69)b
HBeAg-negation0.55 (0.17, 1.72)2.45 (0.77, 8.23)
ALT normal/ HBeAg & HBVDNA-negation0.55 (0.17, 1.72)2.45 (0.77, 8.23)